GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abionyx Pharma (XPAR:ABNX) » Definitions » Total Equity

Abionyx Pharma (XPAR:ABNX) Total Equity : €7.92 Mil (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Abionyx Pharma Total Equity?

Abionyx Pharma's total equity for the quarter that ended in Dec. 2023 was €7.92 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Abionyx Pharma Total Equity Historical Data

The historical data trend for Abionyx Pharma's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abionyx Pharma Total Equity Chart

Abionyx Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.67 6.63 10.68 7.17 7.92

Abionyx Pharma Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.68 8.64 7.17 4.79 7.92

Abionyx Pharma Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Abionyx Pharma's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=14.834-6.912
=7.92

Abionyx Pharma's Total Equity for the quarter that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=14.834-6.912
=7.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abionyx Pharma Total Equity Related Terms

Thank you for viewing the detailed overview of Abionyx Pharma's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Abionyx Pharma (XPAR:ABNX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abionyx Pharma (XPAR:ABNX) » Definitions » Total Equity
Comparable Companies
XPAR:ALACT XPAR:ALGEN XPAR:GNRO XPAR:ALCLS XPAR:PHXM XPAR:ALVIO XPAR:ALDVI XPAR:SIGHT XPAR:ALCOX XPAR:POXEL OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
609:Germany
Address
33-43 Avenue Georges Pompidou-Bat D2, Balma, FRA, 31130
Website
https://www.abionyx.com
Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.

Abionyx Pharma (XPAR:ABNX) Headlines

No Headlines